Atreca Announces Presentation Of Preclinical Data For Antibody Discovery Program

• Findings Demonstrate Ability of Atreca’s Immune Repertoire Capture™ Technology to Generate and Identify Potent Antibodies in Combination with Kymab’s Kymice™

• High-Affinity Antibodies Show Robust Protection in Preclinical In Vivo Malaria-Challenge Model

• Results Presented at Gordon Research Conference: Antibody Biology & Engineering

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today positive preclinical findings generated using the Company’s Immune Repertoire Capture™ technology, presented at the Gordon Research Conference: Antibody Biology & Engineering, which took place in Galveston, TX, March 20-25, 2016. In a poster titled, “Protective Anti-Malarial Human Antibodies identified from P. falciparum CSP Immunized Kymice™ using Immune Repertoire Capture™ (IRC™)”, a research team including scientists at Atreca and collaborators at leading institutions reported key preclinical research findings, including:

“Protective Anti-Malarial Human Antibodies identified from P. falciparum CSP Immunized Kymice™ using Immune Repertoire Capture™ (IRC™)”

• Atreca’s Immune Repertoire Capture™ technology applied in combination with Kymab’s Kymice™, an Ig-gene humanized mouse platform, identified and generated potent antibodies comprised of human variable genes.
• Atreca identified diverse lineages (or families) of antibodies that bind to a key target, the circumsporozoite protein (CSP) of P. falciparum. Two of these lineages provided potent protection in an in vivo malaria-challenge model, resulting in >99% reduction of liver-stage parasite load.

Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research, stated, “IRC™ enabled identification of multiple lineages containing potent, anti-malarial human antibodies generated by activated mouse B cells. The diversified antibody library that we generated had a high hit rate of binding against the CSP target (34%). Our analyses also provide the foundation for understanding structure-activity relationships that mediate the binding of the antibodies that are efficacious in vivo. Furthermore, we have identified many other antibody sequences in these and other lineages that are highly similar to the efficacious antibodies and may therefore also be active in vivo.”

Dr. Emerling continued, “We are grateful to both the Bill & Melinda Gates Foundation and the PATH Malaria Vaccine Initiative for supporting this critical research.”

“These results disclosed at the Gordon Conference demonstrate the ability of Atreca’s Immune Repertoire Capture™ technology to generate novel antibodies with high in vivo potency from immune responses, as well as multiple lineages containing such antibodies,” commented Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “While our primary focus continues to be on cancer immunotherapy, our IRC™ technology allows us to mine the key phenomenon driving efficacious immune responses in humans and animals in diverse disease settings, including infectious and autoimmune diseases.”

Atreca recently reported use of its Immune Repertoire Capture™ technology to analyze the successful anti-tumor responses in individuals with non-progressing lung adenocarcinoma. Based on this and related research, select antibodies discovered by Atreca have progressed to preclinical testing in in vivo models of cancer, with the goal of selecting candidates to enter into more advanced preclinical studies.

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.